Tiziana Life Sciences Ltd
TLSA
Rank in Stocks
#20402
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and... Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Share Price
$0.6691
Last synced: 2026-11-09
Market Cap
$85.15M
Change (1 day)
-2.86%
Change (1 year)
-61.55%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Tiziana Life Sciences Ltd (TLSA)
Category
Healthcare
Operating Margin for Tiziana Life Sciences Ltd (TLSA)
Operating Margin as of November 2026 TTM: 0.00%
According to Tiziana Life Sciences Ltd's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Tiziana Life Sciences Ltd from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -9,533.33% | 0.00% |
| 2012 | 0.00% | -100.00% |
| 2011 | 352.44% | 0.00% |
| 2010 | 0.00% | -100.00% |
| 2009 | -1,346.43% | -19.62% |
| 2008 | -1,675.00% | -57.94% |
| 2007 | -3,982.81% | 605.62% |
| 2006 | -564.44% | -70.41% |
| 2005 | -1,907.76% | 26.16% |
| 2004 | -1,512.12% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
| 2000 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Tiziana Life Sciences Ltd's operating margin
What was Tiziana Life Sciences Ltd's operating margin in 2025?
In 2025, Tiziana Life Sciences Ltd's operating margin was 0.00%, compared with 0.00% in 2020.
How has Tiziana Life Sciences Ltd's operating margin changed since 2020?
From 2020 to 2025, Tiziana Life Sciences Ltd's operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Tiziana Life Sciences Ltd's operating margin compare with similar companies?
Tiziana Life Sciences Ltd's operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.